Study summary

Another DPP-1 blocker roughly halved flare-ups in a phase 2 trial

SAVE-BE trial (HSK31858) · 226 people, phase 2 · Published May 2025, Lancet Respiratory Medicine

0.41rate ratio for flare-ups vs placebo (40 mg)

What was tested

HSK31858, a once-daily DPP-1 inhibitor pill (20 mg or 40 mg), against placebo for 24 weeks, in adults with frequent flare-ups.

What they found

What it means

A large phase 3 trial is now under way.

Lancet Respir Med, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.